
Livanova (LIVN) Stock Forecast & Price Target
Livanova (LIVN) Analyst Ratings
Bulls say
LivaNova has demonstrated robust growth, with sales increasing by 29% to $803 million in 2024, and management anticipates further revenue growth, projecting sales between $940 million and $955 million for the upcoming year. The company's strategic focus on key markets, with approximately half of its revenue generated in the US and an additional 21% from Europe, positions it favorably within the global medical device sector. Additionally, the potential market share expansion of its aura6000 product, with projections indicating sales could rise substantially from $30 million in 2027 to $280 million by 2029 under favorable conditions, underscores a positive trajectory for future performance.
Bears say
LivaNova faces significant challenges that contribute to a negative outlook on its stock, including anticipated revenue growth slowing to low-single digits, primarily due to ongoing headwinds in its Neuromodulation and Cardiovascular businesses. Additionally, there are concerns about operating margin contraction and the potential for below-consensus earnings, which could further strain the company's financial performance. Risks associated with regulatory approvals, particularly for the aura6000 device, along with slower growth in key segments, exacerbate the uncertainty surrounding LivaNova's future profitability and market position.
This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.
Livanova (LIVN) Analyst Forecast & Price Prediction
Start investing in Livanova (LIVN)
Order type
Buy in
Order amount
Est. shares
0 shares